[OH:1][CH:2]1[C:10]2[C:5](=[N:6][CH:7]=[CH:8][N:9]=2)[C:4](=[O:11])[N:3]1[C:12]1[CH:21]=[CH:20][C:19]2[C:14](=[N:15][C:16]([Cl:22])=[CH:17][CH:18]=2)[N:13]=1.C(N(CC)CC)C.[C:30](Cl)(=[O:34])[C:31]([CH3:33])=[CH2:32]>C(Cl)Cl.CN(C)C1C=CN=CC=1>[C:30]([O:11][CH:4]1[C:5]2[C:10](=[N:9][CH:8]=[CH:7][N:6]=2)[C:2](=[O:1])[N:3]1[C:12]1[CH:21]=[CH:20][C:19]2[C:14](=[N:15][C:16]([Cl:22])=[CH:17][CH:18]=2)[N:13]=1)(=[O:34])[C:31]([CH3:33])=[CH2:32]The procedure is as in Example 7, but starting with 5-hydroxy-6-(7-chloro-1,8-naphthyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine (6.3 g) in methylene chloride (80 cc), triethylamine (5.05 g), methacryloyl chloride (3.14 g) and 4-dimethylaminopyridine (50 mg). The residue obtained is purified by recrystallization in acetonitrile followed by chromatography on neutral alumina (50 g) contained in a column 1.5 cm in diameter, eluting with methylene chloride and collecting 15-cc fractions. Fractions 12 to 34 are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40° C. 6-(7-Chloro-1,8-naphthyridin-2yl)-7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b]-pyrazin-5yl methacrylate (1.4 g), m.p. 255° C., is thereby obtained.
読み込み中…
